Review Opinions of the Nomination Committee of the Third Board of Directors on Candidates for Independent Directors of the Third Board of Directors

Yuekang Pharmaceutical Group Co., Ltd.

Nomination Committee of the Third Session of the Board of Directors

Review Opinions on Candidates for Independent Directors of the Third Session of the Board of Directors

In accordance with the relevant provisions of the Company Law of the People's Republic of China (hereinafter referred to as the "Company Law"), the Securities Law of the People's Republic of China, the Measures for the Administration of Independent Directors of Listed Companies, the Shanghai Stock Exchange's Science and Technology Innovation Board Stock Listing Rules, and the Articles of Association of Yuekang Pharmaceutical Group Co., Ltd., the Nomination Committee of the third board of directors of Yuekang Pharmaceutical Group Co., Ltd. (hereinafter referred to as the "Company") reviewed the qualifications of Mr. He Jingfeng, the candidate for independent director of the third board of directors, and issued the following review opinions:

After reviewing the personal resume and other relevant information of Mr. He Jingfeng, the independent director candidate to be nominated this time by the third session of the Board of Directors of the company, it is believed that his educational background, professional ability, work experience and professional qualities meet the requirements for the position he intends to hold, and he has the ability to perform the duties of an independent director. As of now, Mr. He Jingfeng does not hold any shares in the company and has no relationship with the company’s controlling shareholders, actual controllers, shareholders holding more than 5% of the company’s shares, other directors and senior managers. There are no circumstances that prevent you from serving as an independent director of the company as stipulated in the Company Law, there is no situation that is determined by the China Securities Regulatory Commission as a market ban and is still in the ban, there is no situation that has been punished by the China Securities Regulatory Commission and other relevant departments or the stock exchange, and there is no case filed by the judicial authorities for investigation on suspicion of crime or suspected violation of laws and regulations by the China Securities Regulatory Commission. It is not a person subject to execution for dishonesty, and meets the requirements for qualifications and independence required by relevant laws, administrative regulations, departmental rules, normative documents, etc.

In summary, we agree to nominate Mr. He Jingfeng as an independent director candidate for the company's third board of directors, and agree to submit the proposal to the second meeting of the company's third board of directors for review.

Nomination Committee of the Board of Directors of Yuekang Pharmaceutical Group Co., Ltd.

December 4, 2025